Skip to main content

Table 1 Demographical and adipose tissue data for breast cancer (BC) patients undergoing treatment with anthracyclines and controls

From: Potential role of epicardial adipose tissue as a biomarker of anthracycline cardiotoxicity

  Breast cancer patients   Controls   p
N 32   32   -
Females (n, %) 32 (100)   32 (100)   -
Age (years) 55 (48 to 68)   55 (48 to 67)   0.439
Pathology (n, %) Cancer stage   CT indication   
  II 10 (31) Colon cancer 16 (50) -
  III 13 (41) Liver disease 11 (34) -
  IV 9 (28) Pulmonary lesions 5 (16) -
CT-t0 EAT density (HU) -66 (-71 to -63)   -64 (-74 to -60)   0.439
CT-t0 SAT density (HU) -107 (-111 to -105)   -104 (-109 to -101)   0.030
CT-t0 VAT density (HU) -107 (-112 to -102)   -106 (-113 to -97)   0.501
Interval CT-t0–CT-t1 (months) 31 (20 to 53)   27 (13 to 43)   0.162
  1. CT computed tomography, CT-t0 baseline CT, CT-t1 follow-up CT, EAT epicardial adipose tissue, SAT subcutaneous adipose tissue, VAT visceral adipose tissue, HU Hounsfield units. Quantitative data are reported as median and interquartile range